Henry Schein, Inc. $HSIC Stake Cut by Olstein Capital Management L.P.

Olstein Capital Management L.P. decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 11.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 89,000 shares of the company’s stock after selling 11,000 shares during the period. Henry Schein comprises about 1.4% of Olstein Capital Management L.P.’s portfolio, making the stock its 26th largest holding. Olstein Capital Management L.P. owned approximately 0.08% of Henry Schein worth $6,727,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of HSIC. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein during the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein in the second quarter worth about $27,000. Flagship Harbor Advisors LLC acquired a new position in Henry Schein in the fourth quarter valued at approximately $30,000. Steph & Co. acquired a new position in Henry Schein in the fourth quarter valued at approximately $52,000. Finally, Tema Etfs LLC bought a new position in shares of Henry Schein during the fourth quarter valued at approximately $56,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In related news, CEO Thomas C. Popeck sold 1,355 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the sale, the chief executive officer owned 86,182 shares of the company’s stock, valued at $6,273,187.78. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the transaction, the director owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This represents a 11.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 105,911 shares of company stock valued at $8,574,982. 0.89% of the stock is currently owned by insiders.

Henry Schein Stock Down 2.7%

HSIC opened at $70.50 on Friday. The stock’s 50 day moving average price is $76.06 and its 200 day moving average price is $75.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.76. The stock has a market cap of $8.09 billion, a P/E ratio of 21.30, a P/E/G ratio of 1.82 and a beta of 0.82. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the previous year, the firm posted $1.15 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts predict that Henry Schein, Inc. will post 5.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on HSIC shares. Robert W. Baird set a $97.00 price target on Henry Schein in a report on Wednesday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research report on Monday. Barrington Research set a $97.00 target price on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Mizuho reduced their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, UBS Group reaffirmed a “neutral” rating and issued a $85.00 price objective (down from $87.00) on shares of Henry Schein in a report on Wednesday. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $86.83.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.